Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
125.42
-1.29 (-1.02%)
At close: Jun 27, 2025, 4:00 PM
125.42
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:59 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 20 professional analysts, the 12-month price target for Neurocrine Biosciences stock ranges from a low of $115 to a high of $219. The average analyst price target of $163.2 forecasts a 30.12% increase in the stock price over the next year.
Price Target: $163.20 (+30.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 | 7 | 7 |
| Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Hold | 5 | 4 | 4 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 21 | 20 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $145 | Buy | Reiterates | $145 | +15.61% | Jun 2, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $160 → $154 | Buy | Reiterates | $160 → $154 | +22.79% | May 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $137 → $145 | Buy | Maintains | $137 → $145 | +15.61% | May 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $155 → $165 | Strong Buy | Maintains | $155 → $165 | +31.56% | May 6, 2025 |
| BMO Capital | BMO Capital | Hold Maintains $96 → $115 | Hold | Maintains | $96 → $115 | -8.31% | May 6, 2025 |
Financial Forecast
Revenue This Year
2.74B
from 2.36B
Increased by 16.29%
Revenue Next Year
3.15B
from 2.74B
Increased by 15.08%
EPS This Year
4.01
from 3.29
Increased by 21.77%
EPS Next Year
6.29
from 4.01
Increased by 56.91%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0B | 3.5B | 4.0B | ||
| Avg | 2.7B | 3.2B | 3.5B | ||
| Low | 2.5B | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.3% | 27.8% | 26.6% | ||
| Avg | 16.3% | 15.1% | 11.8% | ||
| Low | 8.2% | 0.8% | -3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.92 | 8.71 | 12.01 | ||
| Avg | 4.01 | 6.29 | 8.52 | ||
| Low | 2.88 | 4.03 | 3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.7% | 117.3% | 91.1% | ||
| Avg | 21.8% | 56.9% | 35.6% | ||
| Low | -12.4% | 0.5% | -43.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.